Collegium Pharmaceutical (NASDAQ: COLL) — Perfil da empresa, notícias e dados financeiros
Collegium Pharmaceutical develops innovative therapies for pain management, focusing on safety and effectiveness.

Collegium Pharmaceutical
Collegium Pharmaceutical (NASDAQ:COLL) is a specialized company focusing on the development and commercialization of innovative therapies for pain management. The company aims to address the significant challenges in the pain management sector, such as the need for safer, abuse-deterrent formulations. Collegium Pharmaceutical is passionate about improving the lives of people suffering from pain and chronic conditions, guiding its project selection and research strategies towards achieving this goal. With a strong commitment to patient care, the company continuously seeks to advance its product portfolio through rigorous research and development, while also exploring strategic partnerships and acquisitions to expand its market reach. The objectives of Collegium Pharmaceutical revolve around delivering high-quality, effective treatments, and ensuring accessibility to those in need, thereby making a meaningful difference in the healthcare landscape.
Resumo
Operações
Produtos e/ou serviços de Collegium Pharmaceutical
- Xtampza ER (oxycodone hydrochloride and naloxone hydrochloride) Extended-Release Tablets: A prescription pain medication used to manage moderate to severe chronic pain when other pain medications are not strong enough.
- Nucynta (hydrocodone bitartrate and acetaminophen) Tablets: A prescription pain medication used to manage moderate to severe pain when other pain medications are not strong enough.
- Development Pipeline: Collegium also has a development pipeline of potential future products focused on pain management and addiction treatment.
equipe executiva do Collegium Pharmaceutical
- Vikram KarnaniCEO, President & Director
- Colleen TupperExecutive VP & CFO
- David DieterExecutive VP, General Counsel & Corporate Secretary
- Thomas B. SmithExecutive VP & Chief Medical Officer
- Ian KarpHead of Investor Relations
- Jessica CotroneSenior Vice President of Corporate Communications & Corporate Affairs
- Jane GonnermanExecutive Vice President of Strategy & Corporate Development
- Dean J. PatrasChief People Officer
- Scott SudduthEVP & Head of Technical Operations
Principais indicadores financeiros
Resultados divulgados pela Collegium Pharmaceutical, em USD.
- Cap. de mercado
- 756,3 mi
- Receita (TTM)
- 808,2 mi
- P/L
- 18.3
- LPA (diluído, TTM)
- 1.3
- Dividend yield
- —
- Margem de lucro
- 5.9%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 780,6 mi | 187,1 mi | 62,9 mi | |
| 631,4 mi | 169,9 mi | 69,2 mi | |
| 566,8 mi | 167 mi | 48,2 mi | |
| 463,9 mi | 33,3 mi | -25 mi |